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INTRODUCTION
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a
rare type of cutaneous lymphoma and is classified as a post-thymic
lymphoproliferative disorder that belongs to a new subset ofmature,
peripheral T-cell neoplasms by the World Health Organization
(WHO) [1]. The disease is characterized clinically by an indolent
course of recurrent, self-healing, or progressive subcutaneous
nodules. These nodules both clinically and histologically resemble
panniculitis. Alternatively, a rapidly progressive course can be seen
with subcutaneous nodules accompanied by constitutional symp-
toms and, in some cases, the development of a potentially fatal
hemophagocytic syndrome with significant cytopenia [2]. Here we
report a teenager with SPTCL whose disease was studied by
positron emission tomography (PET) at the time of diagnosis and
after completion of the treatment.
CASE HISTORY
A17-year-oldAfricanAmerican female presented withmultiple
subcutaneous hard masses throughout her body that started in her
left lower back approximately 3 years ago. Since then, the original
lesion has grown in size and new lesions appeared throughout her
body, which have also enlarged in time. She did not have any history
of fever, weight loss, night sweats, or pruritus. On examination, the
subcutaneous lesions were flat, minimally depressed, and hard with
irregular borders located on the left lower back, right anterior
abdominal wall, bilateral thighs, right arm, and right cheek
measuring up to 4 cm 4 cm in size. The lesions were not tender,
and there was no change in the overlying skin or hypoesthesia. The
remainder of her physical exam was otherwise unremarkable.
She had iron deficiency anemia with hemoglobin of 10.5 g/dl,
increased serum IgG level at 3,120 mg/dl, elevated erythrocyte
sedimentation rate (ESR) at 112 mm/hr, low T lymphocyte count at
650/mcl with normal CD4/CD8 ratio, and high titers against EBV;
VCA-IgM was negative, VCA-IgG 1:640, EA-IgG >1:5,120,
EBNA >1:320. Her ANA, HIV serology, and EBV PCR were
negative and LDH was within normal limits.
Biopsy of abdominal wall mass showed subcutaneous fat
necrosis and diffuse infiltration by pleomorphic lymphoid cells
mixed with histiocytes. Manymitotic figures and karyorrhexis were
present. Atypical lymphocytes with hyperchromatic nuclei were
noted surrounding necrotic adipocytes. Immunohistochemistry
revealed that the atypical lymphocytes stained positively with
T cell markers including CD3, CD4, CD5, and CD8. They were
negative forCD2,CD30,Alk1,CD56,CD20, EBV latentmembrane
protein-1 (LMP-1), and Tia1 staining andEBVin situ hybridization.
Karyotype analysis of the tumor tissue was not successful due to
lack of mitotic figures. T cell receptor (TCR)-gamma was negative
by PCR. However, TCR-beta rearrangement was seen in Eco
R1 enzyme digest, but thiswas not sufficient to account for clonality.
Bone marrow biopsy was negative for lymphoma involvement and
karyotype showed 46, XX. Cerebrospinal fluid did not reveal the
presence of lymphoma cells.
A contrast-enhanced computed tomography (CT) of the neck
and chest demonstrated a 3.6 cm 1.6 cm soft tissue lesion in the
subcutaneous tissue of the right face. Several prominent lymph
nodes measuring up to 1.2 cm in short axis diameter were present in
both axilla. Magnetic resonance imaging (MRI) evaluation of the
abdomen and pelvis with gadolinium contrast demonstrated multi-
ple lesions in the subcutaneous tissues of the abdomen and pelvis
that were heterogeneous in signal on T1-weighted images and
increased signal peripherally on T2-weighted images. The subcuta-
neous lesions enhanced peripherally after the administration of
gadolinium contrast. PET using 2-deoxy-2-[F-18]-fluoro-D-glucose
(FDG), which was performed as described previously [3],
demonstrated numerous foci of abnormal FDG uptake involving
the subcutaneous tissues throughout the body and axillary lymph
nodes without any visceral involvement. The maximum stand-
ardized uptake values (SUV) of FDG uptake by these lesions varied
from 2.6 to 4.3.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), an
uncommon disorder, was diagnosed in a 17-year-old female when
she presented with multiple hard subcutaneous masses that
developed over 3 years. She was treated on chemotherapy consisting
of cyclophosphamide, doxorubicin, vincristine, and prednisone. Pre-
and post-treatment positron emission tomography study demon-
strated dramatic resolution of the subcutaneous lesions indicating its
usefulness in SPTCL staging and treatment response monitoring.
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The patient was treated on CHOP chemotherapy consisting of
cyclophosphamide (750 mg/m2/dose), doxorubicin (50 mg/m2/
dose), vincristine (1.4 mg/m2/dose), and prednisone (100 mg/day
for 5 days) for a total of six courses. There was a remarkable
response with resolution of the nodularity in the lesions that,
however, was associated with hardening of the subcutaneous tissues
and further depression at lesion sites (Fig. 1). The repeat PET study
revealed complete resolution of abnormal FDG uptake in the
involved sites (Fig. 2).
One year after the completion of chemotherapy, the patient
continues to be doing well without any evidence of recurrence.
Despite significant improvement, she continues to have increased
serum IgG level at 1,990 mg/dl, elevated ESR at 32 mm/hr, low
T lymphocyte count at 816/mcl with normal CD4/CD8 ratio and
high EBV titers with negative VCA-IgM and positive VCA-IgG at
1:320, EA 1:2,560, and EBNA >1:320.
DISCUSSION
SPTL is characterized by infiltration of the subcutaneous tissue
by pleomorphic T cells and benign macrophages that mimic lobular
panniculitis. The pertinent histologic features described by the
WHO include neoplastic T cells with preferential involvement of
the subcutaneous tissuewith relative sparing of overlying epidermis
and dermis, rimming of neoplastic cells surrounding individual
fat cells, and clonal TCR gene rearrangement. This disorder is
identified in almost equal numbers of male and females, rarely in
children and the median age of diagnosis is 39 years [4–6]. Cases
with a/bT cell subtype havemuch superior outcome comparedwith
g/dT cell subtype, and it was proposed that these subcategories may
represent different pathologies [7–8].
Presence of hemophagocytosis in some cases [2,8], development
of cases after solid organ transplantation [9], occasional sponta-
neous resolution of lesions, and full recovery of certain cases
following immunosuppressive therapy, particularly with a/b T cell
subtype strongly suggest a component of immune dysregulation in
this disorder. Our patient, most likely to have a/b T cell subtype had
several laboratory evidence of associated immune aberration with
elevated serum IgG level, T lymphocytopenia, and very high EBV
titers without EBV-PCR and EBV-related LMP-1 expression in
tumor cells. She responded to CHOP chemotherapy very well with
improvement in her serum IgG, ESR, T lymphocyte count, and
decrease in EBV EA titer, but without complete normalization,
1 year after the completion of chemotherapy. This may indicate
underlying immune aberration in SPTCL.
The use of ultrasound and Gallium-67 scintigraphy has been
reported in SPTCL [10–11]. The CTof the neck and chest andMRI
of the abdomen and pelvis showed the presence of subcutaneous
lesions and small lymph nodes in our case. However, PET studywas
very sensitive to be able to show all the lesions including the ones
palpated on physical examination and resolution of abnormal FDG
uptake in the involved sites following chemotherapy. In primary
cutaneous non-Hodgkin lymphoma, PET was shown to be useful
for initial staging and restaging following therapy [12]. Three of
five primary cutaneous anaplastic large cell lymphoma cases
were negative by PET, whereas a single patient with SPTCL
was positive in a different retrospective study [13]. Although there
is need for further study, the findings in our case also suggest that
PET provides valuable information in detecting lesions in SPTCL
and may be useful in disease staging and monitoring treatment
response.
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Fig. 1. Right anterior leg lesion shows further depression following
chemotherapy. A: At the time of diagnosis and (B) after the completion
of chemotherapy. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
Fig. 2. Complete resolution of abnormal FDG uptake by the
subcutaneous lesions after chemotherapy. A: At the time of diagnosis
and (B) after the completion of chemotherapy.
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Management of Brain Abscesses in Children Treated for
Acute Lymphoblastic Leukemia
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INTRODUCTION
Brain abscesses are rare in immunocompromised patients, and
mortality rates exceeding 90% have been reported [1–8]. Only few
cases of brain abscesses in children treated for acute lymphoblastic
leukemia (ALL) have been reported [9–14]. Since prognosis was
very dismal and little information about the appropriate manage-
ment of this complication was given, we are reporting on the
successful management of four children with ALL, who developed
brain abscesses during antileukemic therapy.
CASE REPORTS
From January 2001 to February 2008, 68 patients were
diagnosed with ALL at our institution. These children were treated
according to the international treatment protocols ALL BFM 2000
or INTERFANT 06. Awritten informed consent was obtained from
parents or their legal guardians. Supportive care included insertion
of a central venous line, infection prophylaxis with oral amphoter-
icin B, trimethoprim/sulphametoxazole (4/20 mg/kg, 4 times
weekly), and broad spectrum antibiotics or blood products if
necessary. Four children (three males and one female) developed
brain abscesses during antileukemic therapy. Their ages at diagnosis
of ALL were 15, 2, 4, and 0.08 years, respectively. Routine cultures
of the cerebrospinal fluid (CSF) were negative in all cases. Brain
abscesses occurred during induction therapy in three patients and
during reinduction therapy in one patient. At onset of neurologic
symptoms, lumbar puncture and magnetic resonance imaging
(MRI) were performed [15]. When diagnosis of brain abscesses
was confirmed, primary treatment included empirical broad
spectrum antibiotics and liposomal amphotericin B (LAmB).
Additionally, all children underwent treatment with hyperbaric
oxygen (HBO) as previously described [16,17]. Primary treatment
Brain abscesses in children with leukemia or other malignancies
are rare and potentially fatal. We report on four children who
developed brain abscesses during treatment for acute lymphoblastic
leukemia (ALL). All patients received multimodal broad-spectrum
antibiotic therapy and liposomal amphotericin-B in combination
with hyperbaric oxygen. First-line antimicrobial treatment was
modified when a causative organism was isolated. All four patients
survived, with two patients showing complete resolution of neuro-
logical and MRI abnormalities and with two patients still having
residual lesions. To date, all patients are in remission with three
patients still receiving antileukemic therapy. Brain abscesses can be
successfully managed by a multimodality approach even in severely
immunocompromised cancer patients. Pediatr Blood Cancer
2009;52:408–411.  2008 Wiley-Liss, Inc.
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